The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Experts are calling on the government to implement strategies that will better predict future Ozempic shortages.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine ...

Telehealth company Him & Hers Health is taking a very different approach to its Super Bowl ad this year - as its new ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Online pharmacies in England, Wales, and Scotland will have to carry out stricter checks on people who are buying weight loss drugs, under new regulatory guidance. Pharmacists will no longer be able ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...